eli lilly oral glp-1 𝗧𝗵𝗲 𝗼𝗿𝗮𝗹 𝗚𝗟𝗣-𝟭 𝗿𝗮𝗰𝗲 𝗷𝘂𝘀𝘁 𝗶𝗻𝘁𝗲𝗻𝘀𝗶𝗳𝗶𝗲𝗱 𝗔𝗻𝗱 𝗟𝗶𝗹𝗹𝘆 𝗹𝗮𝗻𝗱𝗲𝗱 𝗮 𝗱𝗶𝗿𝗲𝗰𝘁 𝗵𝗶𝘁 𝗼𝗻 𝗡𝗼𝘃𝗼. reported head-to-head trial data showing its candidate orforglipron outperformed Novo Nordisk's US approves new oral weight-loss

While some of the information discussed in this post may cause concern, please speak with your medical physician before attempting any change in an existing treatment regime

In cardiovascular outcome trials (CVOTs) such as Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients (EMPA-REG OUTCOME), CANagliflozin cardioVascular Assessment Study (CANVAS) and The Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) [6], they reduced the onset and progression of DKD, which was confirmed in the dedicated kidney trial The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), which showed a canagliflozin-induced risk reduction for ESKD in people with DKD by 32% [7]

Trulicity (dulaglutide) Approved uses: Adults and children over age 10 with type 2 diabetes, and adults with type 2 diabetes at risk for major cardiovascular events Drug type: Once-weekly injection Doses: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg Cost: With commercial insurance and the Trulicity Savings Card, a three-month prescription can cost as low as $25

This is less common than nausea or vomiting, and symptoms typically improve within 4-8 weeks as tolerance develops

The rats received diluted AA (2 mL, 3% v/v) over 30 s using a 2-mm diameter polyurethane cannula placed 8 cm into the rats anus, and the volume and concentration of AA administered were standardized and reproducible to maintain consistency in the experimental protocol